Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Study completedNCT02788474
What this trial is testing

Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment

Who this might be right for
Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim 347
Testing effectiveness (Phase 2)Ended earlyNCT06317285
What this trial is testing

Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Who this might be right for
Idiopathic Pulmonary Fibrosis
GlaxoSmithKline 158
Not applicableLooking for participantsNCT04160715
What this trial is testing

Korean Idiopathic Pulmonary Fibrosis Registry

Who this might be right for
Idiopathic Pulmonary Fibrosis
Seoul National University Hospital 3,000
Early research (Phase 1)Study completedNCT03422068
What this trial is testing

This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.

Who this might be right for
Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim 15
Large-scale testing (Phase 3)Study completedNCT06037408
What this trial is testing

The Effect of N115 on Coughing in IPF Patients

Who this might be right for
Idiopathic Pulmonary Fibrosis
Cellular Sciences, inc. 50
Large-scale testing (Phase 3)Ended earlyNCT00957242
What this trial is testing

AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

Who this might be right for
Idiopathic Pulmonary Fibrosis
Duke University 145
Not applicableUnknownNCT03692481
What this trial is testing

Evolution of Lung 18FDG Uptake in Patients With Idiopathic Pulmonary Fibrosis and Receiving Pirfenidone

Who this might be right for
Idiopathic Pulmonary Fibrosis
Assistance Publique - Hôpitaux de Paris 50
Testing effectiveness (Phase 2)Study completedNCT05119972
What this trial is testing

Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）

Who this might be right for
Idiopathic Pulmonary Fibrosis (IPF)
Guangdong Raynovent Biotech Co., Ltd 15
Not applicableStudy completedNCT03261037
What this trial is testing

Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period

Who this might be right for
Idiopathic Pulmonary FibrosisInterstitial Lung Disease
Hoffmann-La Roche 178
Not applicableStudy completedNCT03115619
What this trial is testing

Quality of Life Study in Participants With IPF Under Pirfenidone Treatment

Who this might be right for
Idiopathic Pulmonary Fibrosis
Hoffmann-La Roche 102
Early research (Phase 1)Study completedNCT05984992
What this trial is testing

The First-in-human Study of SRN-001 in Healthy Participants

Who this might be right for
Idiopathic Pulmonary Fibrosis
siRNAgen Therapeutics Inc. 25
Early research (Phase 1)Study completedNCT03619616
What this trial is testing

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults

Who this might be right for
Idiopathic Pulmonary Fibrosis(IPF)Solid Tumor
Guangdong Zhongsheng Pharmaceutical Co., Ltd. 40
Large-scale testing (Phase 3)Study completedNCT02739165
What this trial is testing

Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Who this might be right for
Idiopathic Pulmonary Fibrosis
Asahi Kasei Therapeutics Corporation 74
Not applicableStudy completedNCT06179342
What this trial is testing

Multiple Breath Washout as a Method for Diagnosing Lung Diseases

Who this might be right for
Pulmonary FibrosisCOPDAsthma
Wissenschaftliches Institut Bethanien e.V 90
Not applicableLooking for participantsNCT00470327
What this trial is testing

The Natural Progression of Interstitial Lung Disease (ILD)

Who this might be right for
Interstitial Lung DiseasesIdiopathic Pulmonary FibrosisSarcoidosis+1 more
University of Chicago 4,000
Testing effectiveness (Phase 2)Study completedNCT02594839
What this trial is testing

Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease

Who this might be right for
Idiopathic Interstitial PneumoniaInterstitial Lung DiseaseIdiopathic Pulmonary Fibrosis
Federal Research Clinical Center of Federal Medical & Biological Agency, Russia 20
Testing effectiveness (Phase 2)Looking for participantsNCT07447102
What this trial is testing

Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis

Who this might be right for
Idiopathic Pulmonary Fibrosis (IPF)
Dragonboat Biopharmaceutical Company Limited 96
Not applicableStudy completedNCT02803580
What this trial is testing

IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis

Who this might be right for
Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim 209
Not applicableStudy completedNCT00453713
What this trial is testing

Race, Ethnicity, and Diffuse Parenchymal Lung Disease

Who this might be right for
Idiopathic Pulmonary FibrosisInterstitial Lung DiseaseDiffuse Parenchymal Lung Disease
Columbia University 565
Not applicableEnded earlyNCT01151527
What this trial is testing

Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias

Who this might be right for
Idiopathic Interstitial Pneumonias
Duke University 269
Next Page